Skip to content

Study · Observational study · n = 37 · 2026

4 results

Weight Loss With SGLT2 Inhibitors, Semaglutide, and Transcranial Magnetic Stimulation in Type 2 Diabetes and Obesity.

Ferrulli A, Senesi P, Sonaglioni A, Cannavaro D, Massarini S, Macrì C, Cipponeri E, DeFronzo RA, Luzi L

Obesity (Silver Spring, Md.)26 Dec 2025

PMID41451880 (opens in a new tab)DOI10.1002/oby.70105 (opens in a new tab)PepBankPUB-41451880
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with obesity and type 2 diabetes, semaglutide 0.5 mg/week was followed by a weight loss of 5.7 kg after 12 months.

    In plain wordsIn people with obesity and type 2 diabetes, semaglutide was followed by about 5.7 kg of weight loss after 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss with semaglutide at 12 months
    Study

    n = 37

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg/week · 12 monthsAs given in this study (human).

    Measurements

    Weight change
    −5.7 kg
    semaglutide, 12 months

    Source sentences

    Summary
    After 12 months the weight loss with rTMS (-8.2 ± 1.0 kg) was not significantly different from that with semaglutide (-5.7 ± 0.9 kg).
    1 context sentence
    Summary · context
    We included 40 patients with T2D treated with a SGLT2i, 37 patients with T2D treated with the GLP1-RA semaglutide, and 30 patients treated with rTMS in this retrospective comparative analysis. rTMS was administered three times per week for 5 weeks.
  2. 02HumanObservational studyEfficacy outcome

    In patients with obesity and type 2 diabetes, 12-month weight loss with semaglutide did not differ significantly from that with rTMS.

    In plain wordsIn people with obesity and type 2 diabetes, weight loss on semaglutide was not clearly different from weight loss with magnetic brain stimulation.

    Peptide
    Semaglutide
    Outcome
    No significant changeWeight loss, semaglutide versus rTMS
    Study

    n: not reported in source

    Comparator
    Repetitive transcranial magnetic stimulation
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg/week · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    After 12 months the weight loss with rTMS (-8.2 ± 1.0 kg) was not significantly different from that with semaglutide (-5.7 ± 0.9 kg).
    1 context sentence
    Summary · context
    We included 40 patients with T2D treated with a SGLT2i, 37 patients with T2D treated with the GLP1-RA semaglutide, and 30 patients treated with rTMS in this retrospective comparative analysis. rTMS was administered three times per week for 5 weeks.
  3. 03HumanObservational studyEfficacy outcome

    In patients with obesity and type 2 diabetes, semaglutide produced significantly more weight loss than SGLT2 inhibitors over 12 months (p = 0.01).

    In plain wordsIn people with obesity and type 2 diabetes, semaglutide led to more weight loss than SGLT2 inhibitor drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss, semaglutide versus SGLT2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT2 inhibitors
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg/week · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Weight loss with SGLT2i (-2.0 ± 0.7 kg) was significantly less than with both semaglutide (p = 0.01)
    1 context sentence
    Summary · context
    We included 40 patients with T2D treated with a SGLT2i, 37 patients with T2D treated with the GLP1-RA semaglutide, and 30 patients treated with rTMS in this retrospective comparative analysis. rTMS was administered three times per week for 5 weeks.
  4. 04HumanObservational studyEfficacy outcome

    In patients with obesity and type 2 diabetes, body weight declined progressively on semaglutide from month 6 to month 12.

    In plain wordsIn people with obesity and type 2 diabetes, body weight kept falling on semaglutide between months 6 and 12.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight trajectory from month 6 to month 12
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg/week · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    BW declined progressively in patients treated with semaglutide and rTMS.
    1 context sentence
    Summary · context
    We included 40 patients with T2D treated with a SGLT2i, 37 patients with T2D treated with the GLP1-RA semaglutide, and 30 patients treated with rTMS in this retrospective comparative analysis. rTMS was administered three times per week for 5 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.